Litcius/Paper detail

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Nathalie Gaspar, Rajkumar Venkatramani, Stefanie Hecker‐Nolting, Soledad Gallego, Franco Locatelli, Francisco Bautista, Alessandra Longhi, Cyril Lervat, Natacha Entz‐Werlé, Michela Casanova, Isabelle Aerts, Sandra J. Strauss, Estelle Thébaud, Bruce Morland, Adela Cañete, Perrine Marec‐Bérard, Marion Gambart, Claudia Rössig, Chinyere E. Okpara, Cixin He, Lea Dutta, Quentin Campbell‐Hewson

2021The Lancet Oncology90 citationsDOI

Topics & Concepts

MedicineIfosfamideLenvatinibInternal medicineClinical endpointEtoposideTolerabilityOncologyPhases of clinical researchRefractory (planetary science)Febrile neutropeniaProgressive diseaseChemotherapySurgeryClinical trialNeutropeniaAdverse effectCancerPhysicsAstrobiologyThyroid cancerSarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsAngiogenesis and VEGF in Cancer
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study | Litcius